ProMetic Life Sciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ProMetic Life Sciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: axial	2/20/2017 2:49:49 PM
	of 250

NASDAQ and PROMETIC The following is a recent email sent to a Prometic investor by Fred Dumais. Link here. — The inferences are interesting Prometic has stated it would like a ~$10 CAD share price at the time of NASDAQ listing The message reflects considerable optimism about the whole spectrum of Prometic activities -- especially including trials -- in the next 12 months ______________________________________________ 'The fact that we are considering a listing on NASDAQ should not come as a surprise to anyone. We have publicly disclosed that many times already. Have we met with investment advisors on Wall Street? Of course we have, name 1 and chances are we have met with them and their analysts. We have been increasing our exposure to the US investors and market for a while already. Have we mandated an investment adviser for the listing? When we have something to disclose to this effect, we will. Nothing specific to disclose at this point in time Will it be in Q3 2017? Possibly, it may also be in Q4 2017 or later based upon many different variables. We will only do it when we are convinced that every necessary conditions are properly aligned Let me make this very short and simple. ProMetic is interested in listing on NASDAQ. That’s a publicly known fact and has been for a while. With the deep product pipeline we have, it would indeed make perfect sense and would most likely be quickly reflected valuation wise. We will only do so when we judge that we are in a position of strength on all sides (financially, operationally and clinically). We believe we have a few more deliverables to achieve first to be in that optimal position and we are working on all of them as we speak (more clinical data in advanced clinical trial stages, approval of our first plasma-derived product, partnerships and licensing agreements etc…). Rest assured that anything material will as always, be promptly disclosed when ready and finalized. Best regards, Fred' Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next